Sentabr, 2025-Yil
146
THE ROLE OF INFLAMMATORY MARKERS IN THE PROGRESSION OF
CORONARY ARTERY DISEASE
Doʻstov Sardor Qaxramonovich
Cardiologist cardiac politicist of the Central Polyclinic of Samarkand region, Bulungʻur district
central polyclinic
https://doi.org/10.5281/zenodo.17166938
Introduction
Coronary artery disease (CAD) remains one of the leading causes of
morbidity and mortality worldwide, and despite advances in interventional cardiology and
pharmacotherapy, its prevalence continues to rise. Beyond traditional risk factors such as
hypertension, diabetes, dyslipidemia, and smoking, increasing evidence indicates that chronic
inflammation plays a pivotal role in the initiation and progression of atherosclerosis. Inflammatory
markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha
(TNF-α) have been identified as key mediators of vascular endothelial dysfunction, plaque
instability, and thrombotic complications. The measurement of these biomarkers may provide
additional prognostic value in risk stratification, guiding early interventions, and improving
patient outcomes.
Objective
The purpose of this study was to evaluate the clinical significance of
inflammatory markers in the progression of coronary artery disease, to determine their association
with angiographic severity of CAD, and to assess their prognostic value in predicting major
adverse cardiovascular events.
Materials and Methods
A cross-sectional observational study was conducted on 120
patients diagnosed with CAD at Samarkand State Medical University Hospital between 2022 and
2023. Patients were divided into three groups based on angiographic findings: mild, moderate, and
severe CAD. Serum levels of high-sensitivity CRP, IL-6, and TNF-α were measured using
standardized immunoassay techniques. Clinical data including demographic characteristics,
cardiovascular risk factors, and treatment history were collected. Statistical analysis was
performed to evaluate correlations between biomarker levels and disease severity, with
significance set at p<0.05.
Results
Patients with severe CAD demonstrated significantly higher levels of hs-CRP, IL-
6, and TNF-α compared to those with mild or moderate disease. Mean hs-CRP levels were 4.2±1.1
mg/L in the severe group versus 1.8±0.7 mg/L in the mild group (p<0.001). IL-6 levels showed a
twofold increase in severe CAD compared to moderate disease (p=0.002). Elevated TNF-α levels
were strongly associated with multi-vessel involvement and history of recurrent angina.
Multivariate regression analysis indicated that inflammatory markers were independent predictors
of severe coronary stenosis after adjusting for traditional risk factors. Furthermore, patients with
elevated inflammatory markers had a higher incidence of adverse cardiovascular events during six
months of follow-up.
Discussion
The findings support the hypothesis that inflammation is a critical driver of
atherosclerotic progression in CAD patients. Elevated CRP, IL-6, and TNF-α not only reflect
systemic inflammation but also serve as surrogate markers of plaque activity and vulnerability.
These biomarkers may help identify high-risk patients who could benefit from more aggressive
pharmacological interventions such as statins, anti-inflammatory agents, and lifestyle
Sentabr, 2025-Yil
147
modifications. The integration of inflammatory markers into standard clinical practice may
enhance early detection, improve prognostic accuracy, and contribute to personalized treatment
strategies. However, larger prospective studies are necessary to validate these associations and to
determine whether targeted anti-inflammatory therapies can reduce CAD progression and improve
survival.
Conclusion
Inflammatory markers, particularly hs-CRP, IL-6, and TNF-α, are
significantly elevated in patients with severe coronary artery disease and demonstrate strong
correlations with angiographic severity and adverse cardiovascular outcomes. Their evaluation
provides valuable prognostic information beyond traditional risk factors, underlining the
importance of inflammation in the pathogenesis of CAD. Incorporating inflammatory biomarkers
into routine clinical assessment may improve risk stratification, optimize therapeutic decisions,
and ultimately reduce the burden of coronary artery disease.
References
:
1.
Uskov A. et al. Modern methods of therapeutic fasting as a way to overcome the
pharmacoresistance of mental pathology //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 179-185.
2.
Abdukodirova S., . SPECIFIC CHARACTERISTICS AND TREATMENT OF ACUTE
OBSTRUCTIVE BRONCHITIS IN CHILDREN OF EARLY AGE //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 5-8.
3.
Tahirova J. et al. Insomnia problem causes of sleep disorder, help measures at home
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 521-525.
4.
Sultanov S. et al. Long-term salbi effects of the covid-19 pandemic on the health of
existing residents of alcohol addiction //Science and innovation. – 2023. – Т. 2. – №. D11.
– С. 430-438.
5.
Madaminov M., . Breast cancer detection methods, symptoms, causes, treatment //Science
and innovation. – 2022. – Т. 1. – №. D8. – С. 530-535.
6.
Шерназаров
Самандар,
Курбаниязова
ВЕ,
Виктория
Саркисова
Владимировна.(2023).
Клиническое
значение
микробиоты
кишечника
у
новорожденных с геморрагической болезнью. IQRO JURNALI, 2 (2), 867-877
[Электронный ресурс].
7.
Tahirova J., . Symptoms of hymoritis, treatment, methods of folk medicine, prevention
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 983-990.
8.
Jalalova D. et al. СОЧЕТАННАЯ СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ
ПАТОЛОГИЯ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 91-100.
9.
Tohirova J. D. Jalalova TYPES OF HEMORRHAGIC DISEASES //CHANGES IN
NEWBOENS, THEIR EARLY DIAGNOSIS.-2022.
10.
Tahirova J. et al. Neurose causes and mechanisms of development, symptoms, treatment,
prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 515-520.
11.
Kiyomov I., . IMPROVING SURGICAL TREATMENT METHODS FOR PATIENTS
WITH NASAL PATHOLOGY //Science and innovation. – 2023. – Т. 2. – №. D11. – С.
226-231.
Sentabr, 2025-Yil
148
12.
Sarkisova V. et al. CYTOKINE PROFILE IN PATIENTS WITH GRANULOMATOSIS
WITH POLYANGIITIS (WEGENER'S) //Science and innovation. – 2023. – Т. 2. – №.
D11. – С. 336-343.
13.
Sarkisova V., Lapasova Z., O. Rakhmanov INFLAMMATORY DISEASES OF THE
PELVIC WOMEN ORGANS. – 2023.
14.
Jalalova D., Raxmonov X., . РОЛЬ С–РЕАКТИВНОГО БЕЛКА В ПАТОГЕНЕЗЕ
СОСУДИСТЫХ
ЗАБОЛЕВАНИЙ
ОРГАНА
ЗРЕНИЯ
У
БОЛЬНЫХ
АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Science and innovation. – 2022. – Т. 1. – №. D8.
– С. 114-121.
15.
Malakhov A. et al. Modern views on the treatment and rehabilitation of patients with
dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 322-329.
16.
Jalalova D., Raxmonov X., . ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В
РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.
17.
Madaminov M., .Acute tonsillitis (angina) causes, complications, diagnosis, treatment,
prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 771-779.
18.
F. The problem of insomnia causes of sleep disorder, remedies at home //Science and
innovation. – 2023. – Т. 2. – №. D1. – С. 79-84.
19.
Sattarova S., FEATURES OF ELECTROPHYSIOLOGICAL METHODS FOR
GUILLAIN–BARRÉ SYNDROME //Science and innovation. – 2023. – Т. 2. – №. D10. –
С. 199-204.
20.
F. Hymoritis symptoms, treatment, methods of folk medicine, prevention //Science and
innovation. – 2023. – Т. 2. – №. D1. – С. 72-78.
21.
Zhalalova D. et al. INFORMATION POINT OF PERIPHERAL BLOOD INDEXES IN
THE DIAGNOSIS OF THE ETIOLOGY OF OPTIC NERVE DAMAGE //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 124-130.
22.
Madaminov M., . Causes, symptoms, diagnosis and treatment of kidney stones
(urolithiasis). Science and Innovation. 2022; 1.8: 760-765 [Электронный ресурс].
23.
Jalalova D., Raxmonov X., . ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В
РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.
24.
Rotanov, A., . (2023). Elderly epilepsy: neurophysiological aspects of non-psychotic
mental disorders. Science and innovation, 2(D12), 192-197.
25.
Konstantinova, O., . (2023). Clinical and psychological characteristics of patients with
alcoholism with suicidal behavior. Science and innovation, 2(D11), 399-404.
26.
Qizi, T. J. I., . (2022). Treatment of myocardial infarction and first aid. Science and
innovation, 1(D3), 317-320.
27.
Xushvaktova D., . Clinical features of mental disorders in synthetic drug users //Science
and innovation. – 2023. – Т. 2. – №. D10. – С. 242-247.
28.
Solovyova Y. et al. The relevance of psychotic disorders in the acute period of a stroke
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 212-217.
Sentabr, 2025-Yil
149
29.
Solovyova Y. et al. Suicide prevention in adolescents with mental disorders //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 303-308.
30.
Sultanov S. et al. Changes in alcohol behavior during the covid-19 pandemic and beyond
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 302-309.
31.
Sultanov S. et al. The impact of the covid-19 pandemic on the mental state of people with
alcohol addiction syndrome //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 296-
301.
32.
Hamidullayevna X. D., Temirpulatovich T. B. Factors of pathomorphosis of alcoholic
delirium //Iqro jurnali. – 2023. – Т. 1. – №. 2. – С. 721-729.
33.
Sharapova D. et al. Clinical and socio-economic effectiveness of injectable long-term
forms of atypical antipsychotics in schizophrenia //Science and innovation. – 2023. – Т. 2.
– №. D12. – С. 290-295.
34.
Sharapova D., . Psychological factors for the formation of aggressive behavior in the youth
environment //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 404-408.
35.
Ochilov U. et al. The question of the features of clinical and immunological parameters in
the diagnosis of juvenile depression with" subpsychotic" symptoms //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 218-222.
36.
Sharapova D., ., Turayev B. Prevalence of mental disorders in children and adolescents
with cancer and methods of their treatment //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 373-378.
